Evaluation of the COVAX Facility, COVAX Advance Market Commitment (AMC) and COVAX pillar delivery efforts: Management response

Overview

Gavi, the Vaccine Alliance appointed RTI International in consortium with Itad and Genesis Analytics to conduct an evaluation of the COVAX Facility, Gavi COVAX Advance Market Commitment (AMC) and COVAX pillar delivery efforts. The evaluation was conducted over the period 2024–2025.

The evaluation builds on the first two years of the COVAX Facility and Gavi COVAX AMC (2020–2021), which were evaluated through the COVAX Facility and AMC Formative Review and Baseline Study (2023). Importantly, this is the first formal joint evaluation by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi), the United Nations Children’s Fund (UNICEF) and the World Health Organization (WHO); and includes country perspectives, which are crucial for understanding the extent to which COVAX addressed country needs, to inform recommendations to improve effectiveness of future responses.

The evaluation yielded several key lessons, for example: achieving equity requires action both between and within countries. Additionally, having the right mix of agencies – including national and subnational governments, and civil society organizations (CSOs) – along with appropriate functions, skills and competencies, is critical for an end-to-end approach. This includes effective coordination for vaccine product development, to secure supply and to provide delivery support.